Type 1 diabetes-induced hyper-responsiveness to 5-hydroxytryptamine in rat pulmonary arteries via oxidative stress and induction of cyclooxygenase-2

Journal of Pharmacology and Experimental Therapeutics

Volumn 338, Issue 1, 2011, Pages 400-407

  Lopez Lopez, Jose G ^a   Moral Sanz, Javier ^b,d   Frazziano, Giovanna ^b,d   Gomez Villalobos, Maria J ^a   Moreno, Laura ^b,d   Menendez, Carmen ^b,d   Flores Hernandez, Jorge ^a   Lorente, Jose A ^c,d   Cogolludo, Angel ^b,d   Perez Vizcaino, Francisco ^b,d  

^a BENEMÉRITA UNIVERSIDAD AUTÓNOMA DE PUEBLA   (Mexico)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

APOCYNIN; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; CYCLOOXYGENASE 2; INDOMETACIN; INSULIN; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NITRIC OXIDE SYNTHASE; SEROTONIN; SEROTONIN 2A RECEPTOR; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; ENZYME INDUCTION; ENZYME INHIBITION; HEART RIGHT VENTRICLE PRESSURE; INSULIN DEPENDENT DIABETES MELLITUS; LUNG ARTERY; LUNG ENDOTHELIUM; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; RAT; RISK FACTOR; SENSITIVITY ANALYSIS; SYSTOLIC BLOOD PRESSURE;

ANIMALS; BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE II; CYCLOOXYGENASE 2; DIABETES MELLITUS, TYPE 1; ENDOTHELIUM, VASCULAR; ENZYME INDUCTION; MALE; OXIDATIVE STRESS; PULMONARY ARTERY; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; VASOCONSTRICTION;

EID: 79959525067     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.179515     Document Type: Article

References (49)

1. Alexander SP, Mathie A, and Peters JA (2008) Guide to Receptors and Channels (GRAC), 3rd edition. Br J Pharmacol 153 (Suppl 2):S1-S209.
2. Al-Shafei AI, Wise RG, Gresham GA, Bronns G, Carpenter TA, Hall LD, and Huang CL (2002) Non-invasive magnetic resonance imaging assessment of myocardial changes and the effects of angiotensin-converting enzyme inhibition in diabetic rats. J Physiol 538:541-553. (Pubitemid 35175379)
3. Atkinson C, Stewart S, Upton PD, Machado R, Thomson JR, Trembath RC, and Morrell NW (2002) Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation 105:1672-1678. (Pubitemid 34298611)
4. Bonnet S, Michelakis ED, Porter CJ, Andrade-Navarro MA, Thébaud B, Bonnet S, Haromy A, Harry G, Moudgil R, McMurtry MS, et al. (2006) An abnormal mitochondrial-hypoxia inducible factor-1α-Kv channel pathway disrupts oxygen sensing and triggers pulmonary arterial hypertension in fawn hooded rats: similarities to human pulmonary arterial hypertension. Circulation 113:2630-2641. (Pubitemid 43948012)
5. Brown L, Miller J, Dagger A, and Sernia C (1998) Cardiac and vascular responses after monocrotaline-induced hypertrophy in rats. J Cardiovasc Pharmacol 31:108-115. (Pubitemid 28027906)
6. Cathcart MC, Tamosiuniene R, Chen G, Neilan TG, Bradford A, O'Byrne KJ, Fitzgerald DJ, and Pidgeon GP (2008) Cyclooxygenase-2-linked attenuation of hypoxia-induced pulmonary hypertension and intravascular thrombosis. J Pharmacol Exp Ther 326:51-58. (Pubitemid 351872115)
7. Coggins MP and Bloch KD (2007) Nitric oxide in the pulmonary vasculature. Arterioscler Thromb Vasc Biol 27:1877-1885. (Pubitemid 47315641)
8. Cogolludo A, Frazziano G, Cobeño L, Moreno L, Lodi F, Villamor E, Tamargo J, and Perez-Vizcaino F (2006a) Role of reactive oxygen species in Kv channel inhibition and vasoconstriction induced by TP receptor activation in rat pulmonary arteries. Ann NY Acad Sci 1091:41-51. (Pubitemid 47092223)
9. Cogolludo A, Moreno L, Lodi F, Frazziano G, Cobeño L, Tamargo J, and Perez-Vizcaino F (2006b) Serotonin inhibits voltage-gated K+ currents in pulmonary artery smooth muscle cells: role of 5-HT2A receptors, caveolin-1, and KV1.5 channel internalization. Circ Res 98:931-938.
10. Chan SY and Loscalzo J (2008) Pathogenic mechanisms of pulmonary arterial hypertension. J Mol Cell Cardiol 44:14-30.
11. Chida M and Voelkel NF (1996) Effects of acute and chronic hypoxia on rat lung cyclooxygenase. Am J Physiol Lung Cell Mol Physiol 270:L872-L878.
12. Christman BW, McPherson CD, Newman JH, King GA, Bernard GR, Groves BM, and Loyd JE (1992) An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 327:70-75.
13. Eddahibi S, Guignabert C, Barlier-Mur AM, Dewachter L, Fadel E, Dartevelle P, Humbert M, Simonneau G, Hanoun N, Saurini F, et al. (2006) Cross talk between endothelial and smooth muscle cells in pulmonary hypertension: critical role for serotonin-induced smooth muscle hyperplasia. Circulation 113:1857-1864. (Pubitemid 43739397)
14. Fouty B (2008) Diabetes and the pulmonary circulation. Am J Physiol Lung Cell Mol Physiol 295:L725-L726.
15. Fredenburgh LE, Liang OD, Macias AA, Polte TR, Liu X, Riascos DF, Chung SW, Schissel SL, Ingber DE, Mitsialis SA, et al. (2008) Absence of cyclooxygenase-2 exacerbates hypoxia-induced pulmonary hypertension and enhances contractility of vascular smooth muscle cells. Circulation 117:2114-2122. (Pubitemid 351572170)
16. 2+, and superoxide anion levels. J Pharmacol Exp Ther 328:19-27.
17. Guignabert C, Izikki M, Tu LI, Li Z, Zadigue P, Barlier-Mur AM, Hanoun N, Rodman D, Hamon M, Adnot S, et al. (2006) Transgenic mice overexpressing the 5-hydroxy-tryptamine transporter gene in smooth muscle develop pulmonary hypertension. Circ Res 98:1323-1330. (Pubitemid 43948088)
18. Hansmann G, Wagner RA, Schellong S, Perez VA, Urashima T, Wang L, Sheikh AY, Suen RS, Stewart DJ, and Rabinovitch M (2007) Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor-gamma activation. Circulation 115:1275-1284. (Pubitemid 46594772)
19. Hernández-Díaz S, Van Marter LJ, Werler MM, Louik C, and Mitchell AA (2007) Risk factors for persistent pulmonary hypertension of the newborn. Pediatrics 120:e272-282.
20. International PPH Consortium, Lane KB, Machado RD, Pauciulo MW, Thomson JR, Phillips JA 3rd, Loyd JE, Nichols WC, and Trembath RC (2000) Heterozygous germline mutations in BMPR2, encoding a TGF-β receptor, cause familial primary pulmonary hypertension. Nat Genet 26:81-84.
21. Jarajapu YP, Guberski DL, Grant MB, and Knot HJ (2008) Myogenic tone and reactivity of cerebral arteries in type II diabetic BBZDR/Wor rat. Eur J Pharmacol 579:298-307.
22. Keaney JF Jr. and Loscalzo J (1999) Diabetes, oxidative stress, and platelet activation. Circulation 99:189-191. (Pubitemid 29056355)
23. Keegan A, Morecroft I, Smillie D, Hicks MN, and MacLean MR (2001) Contribution of the 5-HT(1B) receptor to hypoxia-induced pulmonary hypertension: converging evidence using 5-HT(1B)-receptor knockout mice and the 5-HT(1B/1D)-receptor antagonist GR127935. Circ Res 89:1231-1239. (Pubitemid 34627883)
24. Lam CF, Peterson TE, Croatt AJ, Nath KA, and Katusic ZS (2005) Functional adaptation and remodeling of pulmonary artery in flow-induced pulmonary hypertension. Am J Physiol Heart Circ Physiol 289:H2334-H2341. (Pubitemid 41698540)
25. Le Cras TD, Kim DH, Markham NE, and Abman AS (2000) Early abnormalities of pulmonary vascular development in the Fawn-Hooded rat raised at Denver's altitude. Am J Physiol Lung Cell Mol Physiol 279:L283-L291.
26. Long L, MacLean MR, Jeffery TK, Morecroft I, Yang X, Rudarakanchana N, Southwood M, James V, Trembath RC, and Morrell NW (2006) Serotonin increases susceptibility to pulmonary hypertension in BMPR2-deficient mice. Circ Res 98:818-827.
27. Lopez-Lopez JG, Moral-Sanz J, Frazziano G, Gomez-Villalobos MJ, Flores-Hernandez J, Monjaraz E, Cogolludo A, and Perez-Vizcaino F (2008) Diabetes induces pulmonary artery endothelial dysfunction by NADPH oxidase induction. Am J Physiol Lung Cell Mol Physiol 295:L727-L732.
28. MacLean MR, Herve P, Eddahibi S, and Adnot S (2000) 5-Hydroxytryptamine and the pulmonary circulation: receptors, transporters and relevance to pulmonary arterial hypertension. Br J Pharmacol 131:161-168.
29. MacLean MR, Sweeney G, Baird M, McCulloch KM, Houslay M, and Morecroft I (1996) 5-Hydroxytryptamine receptors mediating vasoconstriction in pulmonary arteries from control and pulmonary hypertensive rats. Br J Pharmacol 119:917-930. (Pubitemid 26366487)
30. Makarevich AE, Valevich VE, and Pochtavtsev AU (2007) Evaluation of pulmonary hypertension in COPD patients with diabetes. Adv Med Sci 52:265-272.
31. Meigs JB, Larson MG, Fox CS, Keaney JF Jr, Vasan RS, and Benjamin EJ (2007) Association of oxidative stress, insulin resistance, and diabetes risk phenotypes: the Framingham Offspring Study. Diabetes Care 30:2529-2535. (Pubitemid 47547788)
32. Moreno L, Losada B, Cogolludo A, Lodi F, Lugnier C, Villamor E, Moro M, Tamargo J, and Pérez-Vizcaíno F (2004) Postnatal maturation of phosphodiesterase 5 (PDE5) in piglet pulmonary arteries: activity, expression, effects of PDE5 inhibitors, and role of the nitric oxide/cyclic GMP pathway. Pediatr Res 56:563-570. (Pubitemid 39280909)
33. Morty RE, Nejman B, Kwapiszewska G, Hecker M, Zakrzewicz A, Kouri FM, Peters DM, Dumitrascu R, Seeger W, Knaus P, et al. (2007) Dysregulated bone morphogenetic protein signaling in monocrotaline-induced pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol 27:1072-1078. (Pubitemid 46641959)
34. Movahed MR, Hashemzadeh M, and Jamal MM (2005) The prevalence of pulmonary embolism and pulmonary hypertension in patients with type II diabetes mellitus. Chest 128:3568-3571. (Pubitemid 41698694)
35. Pidgeon GP, Tamosiuniene R, Chen G, Leonard I, Belton O, Bradford A, and Fitzgerald DJ (2004) Intravascular thrombosis after hypoxia-induced pulmonary hypertension: regulation by cyclooxygenase-2. Circulation 110:2701-2707. (Pubitemid 39453022)
36. Rabinovitch M (2008) Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest 118:2372-2379.
37. Rakotoniaina Z, Guerard P, Lirussi F, Rochette L, Dumas M, Goirand F, and Bardou M(2008) Celecoxib but not the combination of celecoxib + atorvastatin prevents the development of monocrotaline-induced pulmonary hypertension in the rat. Naunyn Schmiedebergs Arch Pharmacol 378:241-251.
38. Rodat L, Savineau JP, Marthan R, and Guibert C (2007) Effect of chronic hypoxia on voltage-independent calcium influx activated by 5-HT in rat intrapulmonary arteries. Pflugers Arch 454:41-51. (Pubitemid 46355864)
39. Rutter MK, Meigs JB, Sullivan LM, D'Agostino RB Sr, and Wilson PW (2005) Insulin resistance, the metabolic syndrome, and incident cardiovascular events in the Framingham Offspring Study. Diabetes 54:3252-3257. (Pubitemid 43334382)
40. Sato K, Li J, Metais C, Bianchi C, and Sellke F (2000) Increased pulmonary vascular contraction to serotonin after cardiopulmonary bypass: role of cyclooxygenase. J Surg Res 90:138-143. (Pubitemid 30314451)
41. Shi Y and Vanhoutte PM (2008) Oxidative stress and COX cause hyper-responsiveness in vascular smooth muscle of the femoral artery from diabetic rats. Br J Pharmacol 154:639-651. (Pubitemid 351744941)
42. Takahashi H, Goto N, Kojima Y, Tsuda Y, Morio Y, Muramatsu M, and Fukuchi Y (2006) Downregulation of type II bone morphogenetic protein receptor in hypoxic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 290:L450-L458. (Pubitemid 43725089)
43. Thomas BJ and Wanstall JC (2003) Alterations in pulmonary vascular function in rats exposed to intermittent hypoxia. Eur J Pharmacol 477:153-161. (Pubitemid 38373532)
44. Wang SN, Lapage J, and Hirschberg R (2001) Loss of tubular bone morphogenetic protein-7 in diabetic nephropathy. J Am Soc Nephrol 12:2392-2399. (Pubitemid 33021116)
45. Watts IS, Zakrzewski JT, and Bakhle YS (1982) Altered prostaglandin synthesis in isolated lungs of rats with streptozotocin-induced diabetes. Thromb Res 28:333-342. (Pubitemid 13254966)
46. Yang X, Sheares KK, Davie N, Upton PD, Taylor GW, Horsley J, Wharton J, and Morrell NW (2002) Hypoxic induction of cox-2 regulates proliferation of human pulmonary artery smooth muscle cells. Am J Respir Cell Mol Biol 27:688-696. (Pubitemid 35381177)
47. Yeh CH, Chang CK, Cheng MF, Lin HJ, and Cheng JT (2009) Decrease of bone morphogenetic protein-7 (BMP-7) and its type II receptor (BMP-RII) in kidney of type 1-like diabetic rats. Horm Metab Res 41:605-611.
48. Yuan JX, Aldinger AM, Juhaszova M, Wang J, Conte JV Jr, Gaine SP, Orens JB, and Rubin LJ (1998) Dysfunctional voltage-gated K+ channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. Circulation 98:1400-1406. (Pubitemid 28462800)
49. Zamanian RT, Hansmann G, Snook S, Lilienfeld D, Rappaport KM, Reaven GM, Rabinovitch M, and Doyle RL (2009) Insulin resistance in pulmonary arterial hypertension. Eur Respir J 33:318-324.